- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2194-7236
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The microbiome of kidney stones and urine of patients with nephrolithiasis ; volume:51 ; number:1 ; day:4 ; month:1 ; year:2023 ; pages:1-10 ; date:12.2023
Urolithiasis ; 51, Heft 1 (4.1.2023), 1-10, 12.2023
- Urheber
-
Lemberger, Ursula
Pjevac, Petra
Hausmann, Bela
Berry, David
Moser, Daniel
Jahrreis, Victoria
Özsoy, Mehmet
Shariat, Shahrokh F.
Veser, Julian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00240-022-01403-5
- URN
-
urn:nbn:de:101:1-2023031320591755687758
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-14T11:00:26+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lemberger, Ursula
- Pjevac, Petra
- Hausmann, Bela
- Berry, David
- Moser, Daniel
- Jahrreis, Victoria
- Özsoy, Mehmet
- Shariat, Shahrokh F.
- Veser, Julian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Über die Bestimmung von Thyroxin im Urin bei Nephrolithiasis
Nephrolithiasis
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Über die Bestimmung von Thyroxin im Urin bei Nephrolithiasis
Nephrolithiasis
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Über die Bestimmung von Thyroxin im Urin bei Nephrolithiasis
Nephrolithiasis